Companies › Prove pharm
1 active drug program in 2 registered trials: 2 Phase 4; Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Indigotindisulfonate sodium 0.8% Visualization dye for determining ureteral patency | – | Phase 4 | Ureter Injury | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06054880 | Indigotindisulfonate sodium 0.8% | Phase 4 | Ureter Injury | Other | Mar 2026 |
| NCT06085183 | Indigotindisulfonate sodium 0.8% | Phase 4 | Ureter Injury | Other | Dec 2026 |
No annotated target.
–
Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Neuraptive Therapeutics Primus Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.